|
|
           
|
|
|
|
|
|
|
|
 
|
|
Rv0005 More about Rv0005 on TBDB.org More about Rv0005 on TubercuList |
Display all mutations or select a bar from the histogram above to examine in greater detail |
| Rv0005: all mutations (high confidence mutations are highlighted in yellow) | |||||||||||||||
| Primary reference | Polymorphism | Nucleotide position | Codon position | Amino acid | Time period | Origin | Molecular detection method | Gene coverage | Resistance pattern | MIC | Susceptibility testing method | R/Total isolates | R/S isolates with mutation | Additional mutations | High confidence support |
| Feuerriegel S AAC 2009 | CGT/TGT | 1369 | 457 | Arg/Cys | 2003-2006 | Uzbekistan | Sequencing | QRDRs on gyrA and gyrB | OFX | N.S. | BACTEC 460 and MGIT 960 | 26/49 | 1/0 | - | - |
| Duong DA AAC 2009 | TCC/TTC | 1373 | 458 | Ser/Phe | 2005-2007 | Vietnam | Sequencing | QRDRs on gyrA and gyrB | - | - | Proportion method | 109/218 | 1/0 | No other mutation in gyrA or gyrB | - |
| Duong DA AAC 2009 | GAC/CAC | 1414 | 472 | Asp/His | 2005-2007 | Vietnam | Sequencing | QRDRs on gyrA and gyrB | - | - | Proportion method | 109/218 | 1/0 | No other mutation in gyrA or gyrB | - |
| Aubry A AAC 2006 | GAC/CAC | 1414 | 472 | Asp/His | Published 2006 | France | Sequencing | QRDRs on gyrA and gyrB | Strongly resistant to OFX | OFX: 60ug/ml | N.S. | 14/15 | 1/0 | "Ala90Val in gyrA; no other mutations in QRDR of gyrB." | - |
| Pitaksajjakul P Southeast Asian J Trop Med Public Health 2005 | GAC/AAC | 1414 | 472 | Asp/Asn | Published 2005 | Thailand | PCR-SSCP, Sequencing | "320-bp QRDR of gyrA; 429-bp QRDR of gyrB." | INH+RIF+STR+EMB+OFX | N.S. | Absolute concentration method | 35/35 | 1/0 | No further mutations in gyrA or gyrB QRDRs found. | - |
| Duong DA AAC 2009 | GAC/AAC | 1414 | 472 | Asp/Asn | 2005-2007 | Vietnam | Sequencing | QRDRs on gyrA and gyrB | - | - | Proportion method | 109/218 | 1/0 | gyrA D94A | - |
| Duong DA AAC 2009 | GAC/GCC | 1415 | 472 | Asp/Ala | 2005-2007 | Vietnam | Sequencing | QRDRs on gyrA and gyrB | - | - | Proportion method | 109/218 | 1/0 | gyrA A90V | - |
| Duong DA AAC 2009 | GGT/GCT | 1442 | 481 | Gly/Ala | 2005-2007 | Vietnam | Sequencing | QRDRs on gyrA and gyrB | - | - | Proportion method | 109/218 | 1/0 | No other mutation in gyrA or gyrB | - |
| Lee AS Int J Infect Dis 2002 | GAC/GCC | 1514 | 505 | Asp/Ala | - | - | - | - | - | - | - | - | - | - | - |
| Aubry A AAC 2006 | AAC/GAC | 1528 | 510 | Asn/Asp | Published 2006 | France | Sequencing | QRDRs on gyrA and gyrB | "GAT, MOX, LVX, and OFX; strongly resistant to ENX." | GAT: >1, MOX and LVX: 2, OFX: 4, and ENX: 64 | Proportion method | 14/15 | 1/0 | No other mutations in QRDR of gyrA or gyrB. |  |
| Duong DA AAC 2009 | AAC/ACC | 1529 | 510 | Asn/Thr | 2005-2007 | Vietnam | Sequencing | QRDRs on gyrA and gyrB | - | - | Proportion method | 109/218 | 1/0 | gyrA A90V | - |
| Mokrousov I AAC 2008 | AAC/AAA | 1530 | 510 | Gln/Lys | 2004 - 2005 | Taiwan | Sequencing | QRDRs on gyrA and gyrB | OFX, CIP, LVX, and MOX. Out of the 14 FQ-R isolates, 6 (42.9%) were resistant to at least one 1st-line drug, while 4 (28.6%) were multidrug-resistant. | OFX: 8, CIP: 5, LVX: 1, and MOX: 1 | Modified proportion method | 14/420 | 1/0 | No further mutations in gyrA or gyrB QRDRs found. | - |
| Duong DA AAC 2009 | ACC/CCC | 1531 | 511 | Thr/Pro | 2005-2007 | Vietnam | Sequencing | QRDRs on gyrA and gyrB | - | - | Proportion method | 109/218 | 1/0 | gyrA A90V | - |
| Duong DA AAC 2009 | GAA/GTA | 1535 | 512 | Glu/Val | 2005-2007 | Vietnam | Sequencing | QRDRs on gyrA and gyrB | - | - | Proportion method | 109/218 | 1/0 | No other mutation in gyrA or gyrB | - |
| Duong DA AAC 2009 | GAA/ | 1536 | 512 | Glu/Asp | 2005-2007 | Vietnam | Sequencing | QRDRs on gyrA and gyrB | - | - | Proportion method | 109/218 | 1/0 | No other mutation in gyrA or gyrB | - |
| Mokrousov I AAC 2008 | GCG/ACG | 1543 | 515 | Ala/Thr | 2004 - 2005 | Taiwan | Sequencing | QRDRs on gyrA and gyrB | OFX, CIP, LVX, and MOX. Out of the 14 FQ-R isolates, 6 (42.9%) were resistant to at least one 1st-line drug, while 4 (28.6%) were multidrug-resistant. | OFX: 8, CIP: 5, LVX: 1, and MOX: 1 | Modified proportion method | 14/420 | 1/0 | No further mutations in gyrA or gyrB QRDRs found. | - |
| Mokrousov I AAC 2008 | GCG/GTG | 1544 | 515 | Ala/Val | 2004 - 2005 | Taiwan | Sequencing | QRDRs on gyrA and gyrB | OFX, CIP, LVX, and MOX. Out of the 14 FQ-R isolates, 6 (42.9%) were resistant to at least one 1st-line drug, while 4 (28.6%) were multidrug-resistant. | OFX: 8, CIP: 5, LVX: 1, and MOX: 1 | Modified proportion method | 14/420 | 1/0 | No further mutations in gyrA or gyrB QRDRs found. | - |
| Mokrousov I AAC 2008 | CAA/CAT | 1647 | 549 | Gln/His | 2004 - 2005 | Taiwan | Sequencing | QRDRs on gyrA and gyrB | OFX, CIP, LVX, and MOX. Out of the 14 FQ-R isolates, 6 (42.9%) were resistant to at least one 1st-line drug, while 4 (28.6%) were multidrug-resistant. | OFX: 8, CIP: 5, LVX: 1, and MOX: 1 | Modified proportion method | 14/420 | 1/0 | No further mutations in gyrA or gyrB QRDRs found. | - |
Disclaimer: These are all putative mutations found in drug resistant clinical TB isolates. No a priori decisions have been made as to whether these mutations are causally related to resistance or possible secondary mutations. |
|
© 2010 Andreas Sandgren | Supported by the Swedish Research Council | Contact Database Curator |